Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload...
News
Kling Bio partners with Sanofi to accelerate antibody discovery
Collaboration aims to advance next-generation therapeutics and vaccines
4TEEN4 begins trial of antibody therapy for cardiogenic shock
First patient dosed in phase 1b/2a study of procizumab
Ovagen breakthrough boosts yellow fever vaccine yields
Irish biotech’s germ-free egg platform could help close global shortfall
PhoreMost unveils platform to streamline molecular glue drug discovery
GlueSEEKER enables rational design of targeted protein degraders
PharmaTimes Clinical Researcher of the Year – The Americas
Enter this year’s thrilling competition!
AlzeCure to present promising pain therapy ACD440 at NeuPSIG 2025
Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients
Ezmekly becomes first approved EU therapy for NF1-PN in children and adults
EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics
Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression
First patient dosed in BUOY-1 study targeting MDD with or without anxious distress
One Biosciences raises €15 million to advance single-cell oncology platform
Funding to accelerate development of AI-driven tumour profiling tool OneMap
North East NHS launches digital platform to tackle chronic kidney disease
Healthinote rollout aims to improve early detection and patient self-management
Proximie and HistoSonics partner to transform liver tumour treatment in US
Digital operating rooms and histotripsy therapy combine to improve outcomes
NHS England secures access to new cystic fibrosis treatment ALYFTREK
Vertex’s once-daily triple therapy approved for eligible patients aged six and over
MHRA approves first oral treatment for hereditary angioedema attacks
Sebetralstat offers injection-free relief for patients aged 12 and over
Pierre Fabre secures China approval for BRAFTOVI combination in colorectal cancer
New treatment targets BRAFV600E-mutant mCRC after prior therapy
